Famotidine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

法莫替丁是一种竞争性组胺 H2 受体拮抗剂。

Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.(In Vitro):Famotidine (MK-208) is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine (MK-208) Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. Famotidine (MK-208) exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. Famotidine (MK-208) increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.

Famotidine (MK-208) is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine (MK-208) Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. Famotidine (MK-208) exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. Famotidine (MK-208) increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.

——

MK-208 | YM-11170

GPCR/G Protein

Histamine Receptor

H2 receptor

Other Indications

——

76824-35-6

337.45

C8H15N7O2S3

>98% (HPLC)

DMSO: 67 mg/mL (198.54 mM)

N/C(N)=N\C1=NC(CSCC/C(N)=N/S(=O)(N)=O)=CS1

(Z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-N'-sulfamoylpropanimidamide

(-20℃)

With Ice Pack

≥ 2 years